FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound

The FDA has flagged a potential increased risk of a rare vision-loss condition associated with GLP-1 receptor agonists used for weight loss and diabetes, including Novo Nordisk's Wegovy and Eli Lilly's Zepbound. The warning follows the agency's review of evidence pointing to a possible link between the drug class and the eye condition, though regulators did not specify an incidence rate or call for label changes in the notice. The drugs anchor a multibillion-dollar obesity market and are used by millions of patients, making any safety signal closely watched by investors in Novo Nordisk and Eli Lilly. Shares of both companies could react as the market assesses whether the warning escalates into formal labeling updates or broader prescribing caution. Next, investors will watch for company responses, any FDA advisory committee review, and whether prescribing data show a measurable pullback among patients with existing eye conditions.